Evidence map›Paper›PMID 35293597›Full record

ReviewInternational journal of molecular medicine2022

Transforming growth factor‑β family and stem cell‑derived exosome therapeutic treatment in osteoarthritis (Review).

Kwang Ho Yoo, Nikita Thapa, Yong Joon Chwae, Seung Hyun Yoon, Beom Joon Kim, Jung Ok Lee, You Na Jang, Jaeyoung Kim

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kwang Ho Yoo *Department of Dermatology, Chung‑Ang University College of Medicine, Seoul 06973, Republic of Korea.
Nikita Thapa *CK‑Exogene, Inc., Seongnam, Gyeonggi‑do 13201, Republic of Korea.
Yong Joon Chwae *Department of Microbiology, Ajou University School of Medicine, Suwon, Gyeonggi‑do 16499, Republic of Korea.
Seung Hyun YoonDepartment of Physical Medicine and Rehabilitation, Ajou University School of Medicine, Suwon, Gyeonggi‑do 16499, Republic of Korea.
Beom Joon KimDepartment of Dermatology, Chung‑Ang University College of Medicine, Seoul 06973, Republic of Korea.
Jung Ok LeeDepartment of Dermatology, Chung‑Ang University College of Medicine, Seoul 06973, Republic of Korea.
You Na JangDepartment of Dermatology, Chung‑Ang University College of Medicine, Seoul 06973, Republic of Korea.
Jaeyoung KimCK‑Exogene, Inc., Seongnam, Gyeonggi‑do 13201, Republic of Korea.
Chung-Ang University · KRAjou University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoarthritis (OA), although extensively researched, still lacks an effective and safe treatment. The only current treatment option available for advanced OA is joint replacement surgery. This surgery may pose the risks of persistent pain, surgical complications and limited implant lifespan. Transforming growth factor (TGF)‑β has a crucial role in multiple cellular processes such as cell proliferation. Any deterioration in TGF‑β signaling pathways can have an immense impact on OA. Owing to the crucial role of TGF‑β in cartilage homeostasis, targeting it could be an alternative therapeutic approach. Additionally, stem cell‑based therapy has recently emerged as an effective treatment strategy that could replace surgery. A number of recent findings suggest that the tissue regeneration effect of stem cells is attributed to the paracrine secretion of anti‑inflammatory and chondroprotective mediators or trophic factors, particularly nanosized extracellular vesicles (i.e., exosomes). Literature searches were performed in the MEDLINE, EMBASE, Cochrane Library and PubMed electronic database for relevant articles published before September 2021. Multiple investigators have confirmed TGF‑β3 as a promising candidate which has the chondrogenic potential to repair articular cartilage degeneration. Combining TGF‑β3 with bone morphogenetic proteins‑6, which has synergistic effect on chondrogenesis, with an efficient platform such as exosomes, which themselves possess a chondroprotective function, offers an innovative and more efficient approach to treat injured cartilage. In addition, multiple findings stating the role of exosomes in chondroprotection has also verified a similar fact showing exosomes may be a more favorable choice than the source itself. In the present review, the importance of TGF‑β family in OA and the possibility of therapeutic treatment using stem cell‑derived exosomes are described.

Indexed as

ExosomesOsteoarthritisHumansStem CellsTransforming Growth Factor betaTransforming Growth FactorsTransforming Growth Factor betaTransforming Growth Factorsexosomeosteoarthritisstem celltransforming growth factor‑β family

Identifiers

PMID35293597
PMCPMC8930092
OpenAlexW4221011588

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.